This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Amigo ML, del Canizo MC, Rios A et al. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS Bone Marrow Transplant 1999 23: 997–1002
Traweek ST, Slovak ML, Nademanee AP et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma Blood 1994 84: 957–963
Mach-Pascual S, Legare RD, Lu D et al. Predictive value of clonality assay in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study Blood 1998 91: 4496–4503
Brito-Babapulle F, Catovsky D, Galton DAG . Clinical and laboratory features of the de novo acute myeloid leukaemia with trilineage myelodysplasia Br J Haematol 1987 66: 445–450
Laurenti L, Cicconi S, Di Mario A et al. Late effects of peripheral blood progenitor cell transplantation (PBPCT) on hemopoietic and immunological function Bone Marrow Transplant 1998 21: (Suppl.1): (Abstr.323)
Kahl C, Florschutz A, Muller G et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia Ann Hematol 1997 75: 91–94
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laurenti, L., d'Onofrio, G., Sica, S. et al. Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. Bone Marrow Transplant 26, 241–242 (2000). https://doi.org/10.1038/sj.bmt.1702502
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702502
This article is cited by
-
Second Malignancies after Hematopoietic Stem Cell Transplantation
Current Treatment Options in Oncology (2018)